PharmX Technologies Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Tom Culver

Chief executive officer

AU$219.3k

Total compensation

CEO salary percentage	87.3%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	3.3yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tom Culver's remuneration changed compared to PharmX Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$219k	AU$191k	AU$95k

Compensation vs Market: Tom's total compensation ($USD142.10K) is below average for companies of similar size in the Australian market ($USD298.48K).

Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.

CEO

Tom Culver

less than a year

Tenure

AU$219,292

Compensation

Mr. Tom Culver serves as Head of Wealth & Crypto Services at Douugh Limited since January 2021. Mr. Culver is Goodments Founder & CEO. Mr. Culver is Chief Executive Officer of PharmX Technologies Limited f...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tom Culver	Chief Executive Officer	less than a year	AU$219.29k	no data
Zoe Hillier	Chief Financial Officer	3.3yrs	AU$276.23k	0.10% A$ 43.1k
James Nevile	Chief Operating Officer	3.3yrs	AU$310.49k	0% A$ 0
Sally McDow	Company Secretary	no data	no data	no data

3.3yrs

Average Tenure

Experienced Management: PHX's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jayne Shaw	Independent Non-Executive Director	4.1yrs	AU$97.68k	0.46% A$ 191.9k
Andrew Jonathan Newbery	Non-Executive Director	4.8yrs	AU$185.37k	0.29% A$ 118.2k
Philip England	Non-Executive Chairman	5yrs	AU$324.28k	4.51% A$ 1.9m
Alexander Mellis	Non-Executive Independent Director	less than a year	no data	no data

4.4yrs

Average Tenure

Experienced Board: PHX's board of directors are considered experienced (4.4 years average tenure).

PharmX Technologies Management

Management criteria checks 3/4

Key information

Recent management updates

PharmX Technologies Limited Announces Change of Company Secretary

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

PharmX Technologies Limited Announces Change of Company Secretary

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Less than half of directors are independent

Less than half of directors are independent

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

New major risk - Market cap size

Less than half of directors are independent

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

No independent directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

No independent directors

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

Now 20% undervalued

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

No independent directors

Corum Group Limited Launches Pharmxchange Platform

No independent directors

No independent directors

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

No independent directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

No independent directors

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure